Publisher
Springer Science and Business Media LLC
Reference78 articles.
1. Oftedal L, Maple-Grodem J, Dalen I, Tysnes OB, Pedersen KF, Alves G, Lange J. Association of CSF glucocerebrosidase activity with the risk of incident dementia in patients with Parkinson Disease. Neurology. 2023;100:e388–95.
2. Franchi PM, Kulagina N, Ilinskaya A, Hoffpauir B, Qian MG, Sugimoto H. Multifaceted approach for quantification and enzymatic activity of Iduronate-2-Sulfatase to support developing gene therapy for Hunter Syndrome. AAPS J. 2023;25:61.
3. European Medicines Agency. Hemgenix. 2023. https://www.ema.europa.eu/en/medicines/human/EPAR/hemgenix. Accessed 31 Dec 2023.
4. U.S. Food and Drug Administration. Human gene therapy for hemophilia: Guidance for industry. 2020. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/human-gene-therapy-hemophilia. Accessed 31 Dec 2023.
5. Felbor U, Kessler B, Mothes W, Goebel HH, Ploegh HL, et al. Neuronal loss and brain atrophy in mice lacking cathepsins B and L. Proc Natl Acad Sci U S A. 2002;99:7883–8.